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Background: Pompe disease is an autosomal recessive metabolic neuromuscular disorder caused by a deficiency
of the lysosomal enzyme acid alpha-glucosidase (GAA). It has long been believed that the underlying pathology
leading to tissue damage is caused by the enlargement and rupture of glycogen-filled lysosomes. Recent studies
have also implicated autophagy, an intracellular lysosome-dependent degradation system, in the disease
pathogenesis. In this study, we characterize the long-term impact of enzyme replacement therapy (ERT) with
recombinant human GAA (rhGAA) on lysosomal glycogen accumulation and autophagy in some of the oldest
survivors with classic infantile Pompe disease (IPD).
Methods: Muscle biopsies from 8 [4 female, 4 male; 6 cross-reactive immunologic material (CRIM)-positive, 2
CRIM-negative] patients with a confirmed diagnosis of classic IPD were examined using standard histopathological
approaches. In addition, muscle biopsies were evaluated by immunostaining for lysosomal marker (lysosomal-associated
membrane protein-2; LAMP2), autophagosomal marker (microtubule-associated protein 1 light chain 3; LC3), and acid
and alkaline ATPases. All patients received rhGAA by infusion at cumulative biweekly doses of 20–40 mg/kg.
Results: Median age at diagnosis of classic IPD was 3.4 months (range: 0 to 6.5 months; n = 8). At the time of muscle
biopsy, the patients’ ages ranged from 1 to 103 months and ERT duration ranged from 0 (i.e., baseline, pre-ERT) to
96 months. The response to therapy varied considerably among the patients: some patients demonstrated motor gains
while others experienced deterioration of motor function, either with or without a period of initial clinical benefit. Skeletal
muscle pathology included fiber destruction, lysosomal vacuolation, and autophagic abnormalities (i.e., buildup),
particularly in fibers with minimal lysosomal enlargement. Overall, the pathology reflected clinical status.
Conclusions: This is the first study to investigate the impact of rhGAA ERT on lysosomal glycogen accumulation and
autophagic buildup in patients with classic IPD beyond 18 months of treatment. Our findings indicate that ERT does not
fully halt or reverse the underlying skeletal muscle pathology in IPD. The best outcomes were observed in the two
patients who began therapy early, namely at 0.5 and 1.1 months of age.
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Pompe disease (OMIM 232300) is an autosomal recessive
disorder caused by a deficiency of lysosomal acid alpha-
glucosidase (GAA; OMIM 606800) leading to rapid glyco-
gen accumulation in multiple tissue types, including
skeletal, cardiac, and smooth muscle, and nervous tissue
[1]. The clinical spectrum of Pompe disease varies broadly,
with significant differences existing in age of onset, rate of
disease progression, and overall clinical phenotype. Pompe
disease is typically categorized into infantile and late-onset
forms based on whether clinical symptoms develop prior to
or beyond 1 year of age, respectively [2]. Infantile Pompe
disease (IPD) is further subdivided into either classic or
atypical (i.e., non-classic) forms based on the presence or
absence of cardiomyopathy as a primary feature [3]. Given
the availability of enzyme replacement therapy (ERT) with
recombinant human GAA (rhGAA; alglucosidase alfa;
Myozyme®; Genzyme Corp., Cambridge, MA), most IPD
patients have experienced gains in overall survival and qual-
ity of life [4-7]. However, many previously unknown com-
plications have emerged [8], and the impact of long-term
ERT on the relative contribution of lysosomal and autopha-
gic pathologies to skeletal muscle damage is not known.
In a study involving muscle biopsies performed in 8 IPD
patients at baseline and at 3 and 12 months post-ERT with
Chinese hamster ovary (CHO) cell-derived rhGAA, signifi-
cant variability in overall glycogen clearance was observed
[7,9]. It was also noted that those patients who started
treatment at earlier ages and/or prior to severe motor im-
pairment seemed to have better glycogen clearance [7,9]. In
an earlier study, muscle biopsies obtained from 4 IPD pa-
tients treated for 18 months with rhGAA derived from
rabbit milk showed variable yet appreciable improvements
in skeletal muscle morphology with good correlation be-
tween clinical and histopathological findings [10]. A later
study examining lysosomal and autophagic pathologies in
patients with IPD or late-onset Pompe disease (LOPD) at
baseline and 6 months after the initiation of ERT demon-
strated that autophagic buildup becomes more prominent
as the lysosomal pathology diminishes on therapy [11].
However, no systematic muscle pathology studies have been
conducted beyond 18 months on ERT, although some
ERT-treated survivors with IPD are now over 13 years of
age. These studies are of particular importance and rele-
vance given that residual motor deficits have been docu-
mented in long-term survivors of IPD despite continued
ERT [8,12]. Herein, we present the findings of muscle biop-
sies taken from a series of patients with classic IPD who
have been on ERT for up to 96 months (8 years).
Methods
Patient cohort
Muscle biopsies from 8 (4 male, 4 female; 6 CRIM-
positive, 2 CRIM-negative) patients with classic IPD(including 6 patients from Duke University Medical
Center, Durham, NC, USA and 2 from Rambam Medical
Center, Haifa, Israel) were obtained as part of clinical trials
or concurrent with scheduled surgical procedures. Prior to
biopsy, written informed consent was provided by the re-
spective parents/guardians for all patients under institu-
tional review board-approved protocols. All patients
received rhGAA biweekly by infusion at cumulative doses
of 20–40 mg/kg (U.S. Prescribing Information, Genzyme
Corp., 2006), and the 2 CRIM-negative patients also re-
ceived successful immune-tolerance induction (ITI) ther-
apy [13]. In addition to histopathological and longitudinal
clinical information, data regarding the cumulative dose of
the drug versus time were collected for all patients. Age at
diagnosis and ERT initiation for individual patients and
the patient cohort are shown as raw values and values
corrected to gestational age (CGA) at birth (i.e., corrected
to 40 weeks gestational age if born prior to 40 weeks). Pa-
tients were followed through November 2012, at which
time the database was locked.
Tissue preparation, staining, and microscopy
Biopsy samples were processed for routine histology
and LAMP2/LC3 staining. Hemaotoxylin and eosin (H&E)
and periodic-acid Schiff diastase (PAS-D) staining
were performed according to standard procedures.
Glutaraldehyde-fixed tissue was used to prepare epon-
embedded sections. ATPase staining was performed after
acid and alkaline preincubations according to standard pro-
cedures. LAMP2/LC3 immunostaining was performed on
isolated muscle fibers as previously described [14]. In many
cases, muscle bundles (up to 20 fibers) were isolated instead
of single fibers because of the condition of the tissue and
the small fiber diameter in infantile patients. The following
primary antibodies were used: anti-LC3 (1:250; provided by
Dr. Takashi Ueno, Juntendo University School of Medicine,
Japan) and mouse anti-human LAMP2 monoclonal anti-
body (1:100; BD Biosciences Pharmingen, San Diego, CA).
Alexa Fluor® 488 and 568 secondary antibodies were pur-
chased from Invitrogen™ (Carlsbad, CA). For each patient,
approximately 100 fibers were analyzed by confocal micros-
copy (Zeiss LSM 510 META), and the number of fibers
with autophagic pathology was counted.
Results
Histopathological analyses of skeletal muscle tissue were
performed in 8 (4 male, 4 female; 6 CRIM-positive, 2
CRIM-negative) patients with classic IPD. Demographic
and mutation data for these patients are summarized in
Table 1. Median age at confirmed IPD diagnosis was
3.4 months (range: 0 to 6.5 months) [2.7 months CGA
(range: -0.3 to 5.5 months)]. Median age at ERT initiation
was 5.7 months (range 0.5 to 7.0 months) [5.5 months
CGA (range: 0.2 to 6.0 months)].
Table 1 Baseline demographics, mutations, and clinico-pathological data for the 8 patients with classic infantile Pompe disease
Patient ID
CRIM status












c.1210G > A (p.Asp404Asn)
0 1.1 20/40
Q, 1.0 Good response; only articulatory
disorder remains after 103.9 mo.
Present in 2% of fibers
(biopsy after 96 mo. of ERT)
Q, 13.1





c.1064 T > C (p.Leu355Pro)
homozygous
4.0; 2.6 CGA 7.0; 5.6 CGA 20
Q, 6.7/ 5.3 Initial developmental progress; decline in
muscle strength and function after 89 mo.






c.1802C > T* (p.Ser601Leu)
0.2;−0.3 CGA 5.4; 4.9 CGA 20/40
Q, 5.3/4.8 Initial developmental progress and
motor gains; decline after 56 mo.
Detected on PAS-stained
sections after 12 mo. of ERT
Q, 17.4/16.9





0;−0.3 CGA 0.5; 0.2 CGA 20 Q, 77.5/77.2
Good response; normal gross motor
development, no hypernasal speech
up to 81.1 mo.
Present in 60-70% of fibers
(biopsy after 77 mo. of ERT);




c.1933G > A (p.Asp645Asn)
homozygous
2.7 2.9 20/40
SCM, 85.9 Motor decline after 35 mo.;
gastrostomy tube supplementation
Present in >10% of fibers




c.655G > A (p.Gly219Arg)
homozygous
6.5; 5.5 CGA 7.0; 6.0 CGA 20/40 Q, 56.0/55.0
Motor decline after 14 mo.;
gastrostomy tube supplementation
Present in occasional fibers
(biopsy after 49 mo. of ERT)
7. Female,
African-Am. -
c.2560C > T (p.Arg854X)
homozygous
5.5; 5.0 CGA 6.3; 5.8 CGA 20
Strap, 7.3/6.8 Limited motor gains, invasive ventilation and
gastrojejunostomy tube; death at 21 mo. of age







5.2 6.0 20/40‡ S, 24.0
Severe motor impairment; ventilator
support and gastrojejunostomy tube
Not identifiable due to
severe muscle deterioration
*Allele has two polymorphic sites: c.1726G > A (p.Gly576Ser), c.2065G > A (p.Glu689Lys).
†Allele contains c.1880C > T nucleotide change (p.Ser627Phe); function unknown.
‡Patient 8 received cumulative dose of 40 mg/kg (20 mg/kg weekly). The regimen was increased after one month of therapy.
§Cardiac improvement seen in all patients.
Q: quadriceps muscle.
SCM: sternocleidomastoid muscle.
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pivotal trials of rhGAA [6] had 3 biopsies each; two of 8
patients had 2 biopsies each, and the remaining three pa-
tients had a single biopsy each. Age at the time of biopsy
ranged from 1.0 to 103.0 months, with time on ERT ran-
ging from 0 (i.e., baseline/pre-ERT; n = 3) to 96 months.
Patient-specific ERT dose information is shown in Figure 1.
In all the cases examined, no correlation between the fiber
type and the degree of muscle involvement was observed
(not shown). Each patient’s clinical status and muscle
pathology are presented below and in Table 1.
Patient 1
Patient 1, an Israeli Druze male with an extensive family
history of IPD, was diagnosed with CRIM-positive IPD
soon after birth. ERT (40 mg/kg biweekly by infusion) was
commenced as part of a clinical trial at the age of
1.1 months (also 1.1 months CGA; see patient N in [6]).
Following 17 months of ERT, the patient’s dose was re-
duced to 20 mg/kg biweekly in accordance with the pack-
age insert (alglucosidase alfa; Myozyme®; U.S. Prescribing
Information, 2006, Genzyme Corp., Cambridge, MA).
Hypotonia was absent upon physical examination prior to
the start of ERT. Baseline echocardiography demonstrated
left ventricular hypertrophy (LVH); baseline left ventricu-
lar mass index (LVMI) was above normal at 59.31 g/m2
but normalized following ERT (week 78: 40.76 g/m2; week
104: 52.46 g/m2). The patient began to walk unassisted at
the age of 12 months and remained within the normal
range of developmental milestones for his age group. Cur-
rently, at the age of 8.7 years, he is strong and active. TheFigure 1 Cumulative biweekly dose (mg/kg) of alglucosidase alfa enz
with classic infantile Pompe disease.only clinical sign of Pompe disease is an articulatory dis-
order with prominent nasal speech.
Histologic examination of a quadriceps biopsy taken
2 days prior to ERT initiation (age 1.0 month) showed a
spectrum of fiber involvement ranging from mild vacu-
olation to effacement (i.e., replacement of myocyte myo-
fibrillar structures by visibly-evident glycogen within the
boundary of the muscle cell); more than 10% of fibers
were severely affected (Figure 2A). All fibers were at
least minimally affected, but no obvious autophagic
pathology was seen (Figure 2B).
In a quadriceps biopsy taken after 12 months of ERT
(age 13.1 months), only rare fibers were effaced or severely
vacuolated, and overall glycogen staining appeared to be
substantially less than in the baseline biopsy (Figure 2C).
However, affected fibers and increased interstitial stroma
were seen at a higher magnification (Figure 2D). After
96 months of ERT (age 97.1 months), no glycogen accu-
mulation was seen in most fibers (Figure 2E, F, G, H).
LAMP2/LC3 staining showed mostly intact fibers without
lysosomal pathology (Figure 2I, top), and only about 1/50
fibers contained autophagic buildup, which was limited to
relatively small areas (not exceeding 100 μm) (Figure 2I,
bottom). Altogether, the patient’s minimal lysosomal and
autophagic pathologies parallel his favorable clinical
response.
Patient 2
Patient 2, an Israeli Druze male, was brought to the
metabolic clinic at the age of 4 months; his parents were
concerned that he might be suffering from the sameyme replacement therapy versus time (months) for the 8 patients
Figure 2 Analysis of quadriceps muscle biopsy from Patient 1 prior to and following 12 and 96 months of ERT. (A) Epon-embedded
PAS/Richardson’s-stained section shows mild to extensive vacuolation in many fibers (magnification 25×). (B) At a higher magnification (200×),
it is evident that nearly all fibers are at least mildly affected. (C, D) After 12 months of ERT (age 13.1 months), no effaced fibers are seen, and
there is much less glycogen overall (100× and 200×, respectively). (E, F) After 96 months of ERT (age 97.1 months), there is only subtle
microvacuolar damage in occasional fibers and no evident glycogen accumulation (100× and 630×, respectively). (G, H) H&E-stained paraffin and
PAS-D sections (25× and 630×, respectively) show little interstitial stroma in otherwise normal-looking fibers. (I, top and bottom) LAMP2/LC3
staining (lysosomes: green; autophagosomes: red) demonstrates mostly intact muscle fibers (for example, top); autophagic pathology can be seen
in ~2% of fibers (bottom; arrowheads). Bar: 10 μm.
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year-old brother. On admission, the baby had truncal
hypotonia (severe head lag) and reduced knee reflexes;
levels of serum creatine phosphokinase (CPK), aspartate
aminotransferase (AST), and alanine aminotransferase
(ALT) were elevated. Baseline echocardiography demon-
strated LVH (LVMI not available). Diagnosis of CRIM-
positive IPD was confirmed, and ERT (20 mg/kg biweekly)
was commenced at the age of 7.0 months (5.6 months
CGA) as part of a clinical trial (see patient B in [6]). Car-
diac parameters normalized 3 months following ERT initi-
ation. The patient achieved unsupported sitting by the age
of 9 months and took his first independent steps at
14 months of age. He was able to participate in sports with
his peers from a young age. The only symptoms of Pompe
disease were facial muscle weakness with abnormal articu-
lation and hypernasal resonance, which were partiallyimproved with speech therapy. Since 8 years of age, he has
demonstrated clinical sequelae seen in long-term IPD sur-
vivors, including dysphagia (with episodes of choking dur-
ing meals), muscle weakness, and severe muscle pain
following activities he formerly performed with ease. Cur-
rently, at the age of 9.8 years, he experiences difficulty
climbing stairs and presents with a subtle waddling gait
following strenuous activity. His speech and phonation
have also deteriorated recently.
Histologic examination of a right quadriceps biopsy
taken 9 days prior to ERT (age 6.7 months, or 5.3 months
CGA) initiation showed a spectrum of fiber involvement
ranging from mild vacuolation to effacement; about 10%
of fibers were severely affected, and none appeared en-
tirely normal (Additional file 1: Figure S1A). There was
some fibrosis but autophagic debris was not evident
(Additional file 1: Figure S1B). In a biopsy of the right
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or 17.6 months CGA), fewer fibers appeared effaced or
severely vacuolated (Additional file 1: Figure S1C), and
normal fibers were present (Additional file 1: Figure S1D).
After 96 months of ERT (age 103.0 months, or
101.6 months CGA), a right quadriceps biopsy demon-
strated marked variability in damage; some effaced fasci-
cles, minimally affected fibers, and many normal fibers
were seen (Additional file 1: Figure S1E and S1F, more
affected areas, top; less affected areas, bottom). This was
confirmed on H&E paraffin sections (Additional file 1:
Figure S1G). PAS-D showed an increase in interstitial
stroma, but fibrosis was not prominent even in severely-
affected areas (Additional file 1: Figure S1H). Consistent
with histologic data, LAMP2/LC3 immunostaining after
96 months of ERT showed variable degrees of fiber involve-
ment: occasional fibers with grossly enlarged lysosomes, fi-
bers with modest lysosomal expansion as well as normal
looking fibers. A prominent feature in this biopsy was the
presence of autophagic buildup in most fibers, which was
missed on routine histologic examination; the buildup areas
contained clearly discernible LC3-positive autophagosomes
clustered in proximity to LAMP2-positive lysosomes
(Additional file 1: Figure S1I). Furthermore, many autopha-
gic areas contained autofluorescent balloon-like structures
similar to those found in adult patients with Pompe disease
[15]. Thus, in patient 2, a modest effect of ERT on lyso-
somal pathology and the emergence of autophagic buildup
are likely responsible for the observed clinical deterioration.
Patient 3
Patient 3, a Hispanic female with a family history of
Pompe disease, was diagnosed with CRIM-positive IPD
at the age of 0.2 months (−0.3 months CGA). ERT was
initiated at the age of 5.4 months (4.9 months CGA) at
20 mg/kg biweekly. Due to motor decline after 56 con-
secutive months, the dose was increased to 40 mg/kg bi-
weekly. Baseline echocardiography demonstrated LVH
with LVMI of 266 g/m2; cardiac parameters normalized
by 33 months of age (LVMI 49 g/m2, shortening fraction
41%). The patient achieved independent sitting by
7 months of age, started walking at 14 months of age,
and has always fed by mouth; however, she has received
supplementary overnight gastrostomy tube feeds since
7 years of age. Currently, at 9.4 years, the patient does
not require invasive ventilation, has normal cardiac size
and function, and can ambulate with the assistance of a
walker. She has several features of the evolving pheno-
type of infantile survivors, including ptosis, lingual weak-
ness, myopathic faces, scoliosis, frequent falls, and the
need for ankle-foot orthoses [8]. Like patients 1 and 2,
patient 3 also participated in the original pivotal trial of
alglucosidase alfa (see patient H in [6]). Right quadriceps
biopsies were collected at baseline and 12 months onERT [7,9], and an additional left quadriceps biopsy was
obtained at 91 months of age (85 months on ERT).
Histologic examination of a right quadriceps biopsy
taken 2 days prior to ERT initiation (age 5.3 months, or
4.8 months CGA) showed a spectrum of fiber involvement
ranging from mild vacuolation to effacement; however,
only 10% of fibers were severely affected (Additional file 2:
Figure S2A). There was minimal fibrosis, and no obvious
autophagic debris was seen (Additional file 2: Figure S2B).
In the biopsy taken after 12 months of ERT (age
17.4 months, or 16.9 months CGA), more than half of the
fibers were effaced or severely vacuolated; the tissue was
very fibrotic (Additional file 2: Figure S2C), and autopha-
gic debris was seen in some fibers (Additional file 2: Figure
S2D; circled). After 85 months of ERT (age 90.4 months,
or 89.9 months CGA), the biopsy revealed complete loss
of myofibrillar architecture in all muscle fibers (Additional
file 2: Figure S2E and S2F). Thus, despite increased dose
of ERT, this patient had severe muscle damage and several
clinical sequelae of IPD.
Patient 4
Patient 4, a Caucasian male with a family history of
Pompe disease, was diagnosed prenatally (age 0 months,
or −0.3 months CGA) with CRIM-positive IPD. He was
started on ERT at a cumulative dose of 20 mg/kg bi-
weekly at the age of 0.5 months (0.2 months CGA).
Baseline echocardiography demonstrated mild LVH,
with an LVMI of 70 g/m2; LVMI normalized by
7 months of age (LVMI: 48 g/m2). The patient had nor-
mal gross motor development on ERT, was able to sit
independently by 6.5 months of age, and took his first
unassisted steps at 16 months of age. He has never re-
quired invasive ventilator support and has always fed by
mouth. At the age of 6.8 years he continues to do well,
with independent ambulation, motor gains, and no
hypernasal speech.
Histologic examination of a right quadriceps biopsy
taken after 77 months of ERT (age 77.5 months, or
77.2 months CGA) showed mild pathology with many
normal looking fibers (Additional file 3: Figure S3A), albeit
with increased intramyofibrillar staining. Some fibers were
vacuolated, varying from mild (diffuse vacuolation or 1–2
large vacuoles) to severely affected. Overall, less than 1%
fibers were severely damaged or effaced. The proportion
of affected fibers reached 30% in some fascicles. There was
evidence of limited fiber regeneration (internal nuclei) in
occasional fibers. PAS-D staining showed preservation of
the myofibrillar architecture in most fibers and no obvious
increase in interstitial stroma (Additional file 3: Figure
S3B). Epon-embedded sections revealed relatively pre-
served fiber architecture; autophagic debris was detected
in some fibers (Additional file 3: Figure S3C; circled).
LAMP2/LC3 immunostaining showed autophagic buildup
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case, autophagic pathology appears to be the major abnor-
mality in skeletal muscle after 77 months of treatment.
Autofluorescent inclusions, similar to those seen in fibers
from patient 2, were detected in this patient’s biopsy
(Additional file 3: Figure S3D). Similar to patient 1, this in-
dividual commenced ERT at a very early age, and his clin-
ical status compares favorably to the others.
Patient 5
Patient 5, a Caucasian male, presented at the age of
2 months with an upper respiratory tract infection; he
had marked cardiomegaly on a chest x-ray obtained to
evaluate this condition. The patient was diagnosed with
CRIM-positive IPD and began ERT at 2.9 months of age
(also 2.9 months CGA) with a cumulative biweekly dose
of 20 mg/kg for the first 35 months and 40 mg/kg subse-
quently due to motor decline. At baseline, marked LVH
(LVMI of 239 g/m2 and EF 45%) was present. Significant
improvement in cardiac function and size was seen early-
on during therapy, with normalization of cardiac parame-
ters by 12 months (LVMI: 41 g/m2). Swallowing difficulties
necessitated gastrostomy tube supplementation for nutri-
tion. He is currently 99 months (8 years, 3 months) old,
has a normal LVMI, has never required invasive ventila-
tion, continues to receive gastrostomy tube supplementa-
tion, and is able to walk independently although he has an
abnormal gait and ankle contractures.
Histologic examination of a right quadriceps biopsy
taken during port revision surgery after 84 months of ERT
(age 86.9 months) showed striking variation in pathology
between fascicles (Additional file 4: Figure S4A). There
was evidence of fiber regeneration (internal nuclei) in the
less damaged part of the biopsy. PAS-D staining demon-
strated preservation of the myofibrillar architecture of
some fibers and obliteration of the adjacent ones, with
mild fibrosis (Additional file 4: Figure S4B, left and right).
Epon-embedded sections and LAMP2/LC3 immunostain-
ing confirmed this striking variability ranging from well-
preserved fibers with minimal or no lysosomal pathology
[10% of which contained autophagic buildup (not shown)]
to severely affected fibers (Additional file 4: Figure S4C
and S4D, respectively).
Similarly, histologic examination and LAMP2/LC3 im-
munostaining of a left sternocleidomastoid (SCM) bi-
opsy after 83 months of ERT (age 85.9 months) showed
prominent damage and variability in muscle pathology
and autophagic buildup (Additional file 4: Figure S4E
and S4F). There was evidence of fiber regeneration and
focal reactive inflammation, Thus, despite increased dose
of ERT, both neck and leg muscles showed significant
pathology, which varied considerably within each muscle
group; this pathology reflects the inadequate clinical re-
sponse with several long-term sequelae in this patient.Patient 6
Patient 6, a Caucasian female, presented with failure to
thrive and congestive heart failure. She was diagnosed
with CRIM-positive IPD at the age of 6.5 months. ERT
was started at 7.0 months (6.0 months CGA) at a cumu-
lative biweekly dose of 20 mg/kg for the first 14 months
and then 40 mg/kg subsequently due to clinical plateau.
Baseline echocardiography demonstrated marked LVH
(with LVMI of 224 g/m2), which essentially normalized
by 22 months of age (LVMI: 64.9 g/m2). Right quadri-
ceps muscle biopsy was obtained at 56 months of age
(49 months on ERT) during bilateral hip contracture re-
lease. At the time of surgery, the patient was able to
maintain quadruped independently for 1 minute or
stand with support for a few seconds. The patient has al-
ways been orally fed with gastrostomy tube supplemen-
tation, but has never been ventilator dependent.
Histologic examination of a right quadriceps biopsy taken
after 49 months of ERT (age 56.0 months, or 55.0 months
CGA) showed severe skeletal muscle pathology. H&E-
stained sections revealed replacement of the sarcoplasm of
the majority of muscle fibers by hematoxophilic material;
the severely damaged and relatively unaffected fibers were
randomly distributed irrespective of fiber type (data not
shown) (Additional file 5: Figure S5A). There was evidence
of fiber regeneration (internal nuclei) in some of the intact
fibers. PAS-D staining confirmed moderate fibrosis
(Additional file 5: Figure S5B) and highlighted the dichot-
omy of damage with preservation of the myofibrillar archi-
tecture of some fibers and obliteration of adjacent ones.
Epon-embedded sections and LAMP2/LC3 immunostain-
ing confirmed this heterogeneity (Additional file 5: Figure
S5C and S5D). There was fibrosis around both the dam-
aged and undamaged fibers (Additional file 5: Figure S5C).
Autophagic debris was not seen on bright-field microscopy,
but was detected by LAMP/LC3 staining in occasional fi-
bers (Additional file 5: Figure S5D; bottom fiber). In this
case, it appears that even the initial response to ERT was
less dramatic than in other CRIM-positive patients. The pa-
tient’s underlying muscle histopathology correlates well
with the limited improvement in motor function.
Patient 7
Patient 7, an African American female, presented with
decreased muscle tone at birth, feeding difficulties and
weakness of extremities at 2 months, and persistent car-
diomegaly and failure to thrive by the age of 5 months.
The patient was diagnosed with CRIM-negative IPD
at 5.5 months (5.0 months CGA) and began ERT
(20 mg/kg rhGAA biweekly) plus immunomodulation
with methotrexate and rituximab ([13]) at 6.3 months
(5.8 months CGA). Baseline echocardiography demon-
strated marked left ventricular hypertrophy (LVMI of
351.4 g/m2). An anterior neck “strap” muscle biopsy
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7.3 months of age. A marked improvement in LVH
(LVMI: 60.6 g/m2) was observed at the age of 21 months,
and the patient experienced limited motor gains such as
improved head control and increased ability to move
extremities against gravity. However, the patient was
never able to achieve independent sitting or full head
control and continued to require invasive ventilation
and gastrojejunostomy tube placement throughout the
course of ERT. She died unexpectedly at the age of
21 months of a presumed cardiac event.
Histologic examination of an anterior neck “strap” bi-
opsy taken after 1 month of ERT (age 7.3 months, or
6.8 months CGA) showed widespread skeletal muscle
pathology and vacuolization of most fibers. In H&E
stained sections, the myofibrillar architecture was only
partially preserved in about 80% of fibers; 10% appeared
obliterated, and another 10% were relatively unaffected at
this resolution (Figure 3A). PAS-D staining showed diffuse
mild fibrosis, and preservation of much of the internal
architecture in most fibers (Figure 3B). Epon-embedded,
toluidine blue-stained sections revealed multiple vesicular
structures (Figure 3C), but no autophagic debris. LAMP2/
LC3 staining demonstrated extensive damage with only
partial preservation of muscle structure in some fibers
(Figure 3D). On autopsy (following 14 months of ERT),
excess glycogen was found in all tissues examined. A sam-
ple of left quadriceps muscle (age 20.3 months, orFigure 3 Analysis of muscle biopsies from Patient 7 after 1 and 14 m
1 month of ERT (age 7.3 months, or 6.8 months CGA). (A) H&E-stained froz
more than 90% of myocytes; complete loss of myofibrillar architecture in 1
vacuolation of most fibers and increased interstitial stroma; however, much
embedded toluidine blue-stained section highlights the partial replacemen
immunostaining demonstrates extensive damage with only partial preserva
fibers); bright green staining, particularly in the middle fiber, likely indicates
(E) H&E-stained section of post-treatment quadriceps muscle from autopsy
shows extensive damage, which appears to be more severe than that in th19.8 months CGA) showed more severe and diffuse dam-
age than had been seen in the “strap” muscle biopsy taken
13 months before; now there was vacuolization of nearly
all fibers and obliteration of the myofibrillar architecture
in more than 95% of muscle cells (Figure 3E). Thus, des-
pite successful ITI, the patient did not survive beyond
21 months of age. Correspondingly, the pathology showed
profound muscle destruction.
Patient 8
Patient 8, a Hispanic female, was found to have supra-
ventricular tachycardia and ventricular hypertrophy at
birth. She was diagnosed with CRIM-negative IPD at
the age of 5.2 months (also 5.2 months CGA) and re-
ceived biweekly infusions of ERT (20 mg/kg biweekly)
with immunomodulation treatment at the age of
6.0 months (also 6.0 months CGA). After 4 weeks, the
frequency of ERT was increased to weekly infusions be-
cause of severe hemidiaphragmatic weakness and hypo-
tonia. A right soleus muscle biopsy was obtained during
a bilateral Achilles tendon lengthening procedure at
24 months of age (18 months of ERT). At the time of bi-
opsy, the patient exhibited severe motor impairments,
including incomplete head control and inability to sit
independently, maintain quadruped, creep or crawl. Al-
though the patient continued to remain ventilator
dependent and rely on gastrojejunostomy tube feeds
throughout the course of ERT, improvement inonths of ERT. A-D: Anterior neck “strap” muscle biopsy taken after
en section shows the extent of damage and fibrosis: vacuolation of
0% of myocytes (magnification 25×). (B) PAS-D staining demonstrates
of the internal fiber architecture is preserved (630×). (C) Epon-
t of sarcoplasm by vesicular structures (630×). (D) LAMP2/LC3
tion of muscle structure (i.e., striations in the top two and bottom
the presence of remnants of lysosomal membranes. Bar: 10 μm.
(i.e., after 14 months of ERT; age 20.3 months, or 19.8 months CGA)
e pre-ERT biopsy (25×).
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cardiogram showed severe biventricular hypertrophy
(LVMI of 318.4 g/m2 and shortening fraction of 26.9%),
but on the follow-up at 24 months of age these parame-
ters became 72.5 g/m2 and 28.3%, respectively.
Histologic examination of a right soleus biopsy taken
after 18 months of ERT (age 24.0 months) showed severe,
diffuse skeletal muscle pathology. H&E-stained sections
revealed vacuolization of nearly all muscle fibers and ex-
tensive loss of the myofibrillar architecture in most fibers
(Additional file 6: Figure S6A). There was mild diffuse fi-
brosis with only lace-like remnants of myofibrillar struc-
ture (Additional file 6: Figure S6B). Both epon-embedded,
toluidine blue-stained sections (S6C) and LAMP2/LC3
immunostaining (S6D) showed complete destruction of
myofibers. Similar to patient 7, this CRIM-negative infant
exhibited significant muscle damage at baseline and
showed a poor response to ERT (despite successful ITI)
both clinically and in terms of tissue morphology.
Discussion
The aim of the present study was to examine histological
findings and clinical symptoms of patients with classic
IPD who had been on ERT for years. Previous studies
examining the effects of ERT on skeletal muscle path-
ology had been limited to 72 weeks of treatment. How-
ever, the availability of therapy has led to the emergence
of what appears to be a “new nosological entity” - skel-
etal muscle myopathy (combined with a series of add-
itional symptoms) in long-term survivors of IPD. These
survivors are a testament to both the successes and limi-
tations of ERT: a dramatic improvement in cardiac func-
tion and prevention of cardiac failure, yet in many cases
only a modest or negligible effect on skeletal muscle.
One of the questions we tried to address was the utility
of muscle biopsy as a prognostic indicator of the patients’
response to ERT. In the three cases for which the pre-ERT
(baseline) biopsies were available (patients 1, 2, and 3),
histological findings appeared similar – variable degree of
fiber involvement, approximately 10% severely damaged fi-
bers, and no detectable autophagic abnormality. However,
the clinical outcome is very different – patient 1 responded
remarkably well, patient 2 began to deteriorate at age 8,
and patient 3 showed a gradual progression of the disease.
On the other hand, in each of the three cases, the findings
on follow-up biopsies seem to correlate well with the clin-
ical data – mostly normal histology with minor autophagic
abnormalities in patient 1, significant skeletal muscle path-
ology in patient 2, and profound muscle destruction in pa-
tient 3. The same correlation was observed in patients 5, 6,
7, and 8, whose biopsies were available at different ages on
ERT – a variable combination of lysosomal and autophagic
pathologies in severely clinically affected children. Thus, al-
though the prognostic value of initial muscle biopsy isquestionable, muscle pathology in follow-up biopsies
reflected clinical response. In none of the cases examined
did we observe a normal or near normal biopsy in a patient
who was significantly clinically affected. The reverse is also
largely true – mildly symptomatic patients did not exhibit
severe pathology. A possible exception is patient 4, who
continues to do well on ERT at 6.8 years despite a promin-
ent autophagic pathology in most fibers. It remains unclear
whether autophagic buildup in this patient would eventu-
ally lead to clinical decline as seems to be the case in
patient 2.
Despite the limitations of muscle biopsy, including great
variability even in different regions of a single biopsy, it is
still useful for monitoring disease severity and response to
ERT. However, the inevitably invasive nature of muscle bi-
opsies hampers longitudinal follow-ups from the same
muscle group in the same patients over time. Further-
more, coordination of muscle biopsies with scheduled sur-
gical procedures renders the site and time of biopsy
entirely dependent on the site and time of surgery. Thus,
consistent sampling from one particular muscle group, as
would have been ideal, could not be achieved. Other mo-
dalities by which the disease severity can be monitored are
currently being implemented. The urinary hexose
tetrasaccharide (Hex4) biomarker that is used for overall
assessment of disease severity and response to ERT
[16,17] does not allow for the evaluation of the extent of
involvement of particular muscle groups. Recent work has
indicated the potential utility of whole-body magnetic res-
onance imaging (MRI) [18,19]. However, this technique
has not yet been systematically evaluated for its ability to
measure subtle changes in muscle pathology and will re-
quire further assessment of its diagnostic and prognostic
potential in Pompe disease.
Although autophagic accumulation can be detected by
routine histological examination of muscle biopsies, par-
ticularly when many fibers are affected (see patients 3 and
4), confocal microscopy and immunostaining of single fi-
bers remains the best way to evaluate autophagic path-
ology. Consistent with our previous observations [11],
autophagic abnormalities were negligible in baseline biop-
sies (patients 1, 2, and 3), but became prominent with
prolonged ERT. Interestingly, autophagic buildup, often
located in the core of muscle fibers, is usually seen in well-
preserved fibers with minimal or no lysosomal pathology
outside the buildup area (patients 1, 2, 4, 5, and 6),
suggesting that these fibers responded to therapy reason-
ably well. In contrast to previous observations in both
humans and mice [9,20-22], we did not see any appre-
ciable difference in the involvement or response to ERT
between type I and type II muscles.
In addition to lysosomal/autophagosomal vesicles (or
remnants of these vesicles), the area of buildup often con-
tains globular autofluorescent material, which is most
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These structures are reminiscent of the acid phosphatase-
positive inclusions detected in adult-onset Pompe patients,
whose muscle pathology showed no typical vacuolated fi-
bers [15]. The origin of these inclusions is not clear, but
their presence in diseased human muscle cells points to
yet another previously unrecognized pathology.
Several patients in this study (patients 2, 3, 5, and 6)
initially showed clinical improvements on therapy, but
they began to deteriorate at different time points ranging
from 14 months in patient 6 to 8 years in patient 2,
prompting the increase in the drug dosage to 40 mg/kg
every 2 weeks (cumulative dose) in patients 3, 5, and 6.
Although there are significant individual differences in
the rates of motor deterioration, this clinical course – a
decline following initial improvement – appears to be an
emerging pattern in IPD patients on ERT, suggesting
that even at extremely high doses of the drug, the ther-
apy does not halt the progression of the disease. The
reported initial decrease and eventual increase in Hex4
levels in patients on therapy [16] seem to mirror the
clinical course, suggesting that indeed the replacement
enzyme does not keep up with the rate of glycogen accu-
mulation, likely due to inefficient delivery. Of note, we
have found that all patients had slightly increased interstitial
collagen and some degree of fibrosis, which may exacerbate
the problem of inefficient delivery of the drug to skeletal
muscle cells. Furthermore, as these patients continue to
grow, they develop previously unrecognized complications
of Pompe disease, such as ptosis, hypernasal speech,
osteopenia, sensorineural and/or conductive hearing loss
and gastroesophageal reflux [8]. Therefore, research into
more effective second generation drugs with enhanced
targeting properties is currently being pursued [23-25].
The pace of disease progression and the rate of clinical
decline vary significantly even among patients with classic
IPD. Although it is not currently feasible to accurately pre-
dict the course, CRIM-negative patients represent the
most vulnerable group. In the two CRIM-negative patients
in this study (patients 7 and 8), the drug failed to keep
pace with the relentless disease progression despite suc-
cessful immune modulation and the removal of high or
sustained anti-rhGAA IgG titers [26-28].
Finally, it has been shown that muscle pathology in
IPD patients develops in utero, and asymptomatic new-
borns may already have a significant number of severely
affected fibers (see baseline biopsy of patient 1) [29-32].
There is a general consensus about the need to start
therapy early before irreversible changes occur (indeed,
the profoundly destroyed muscle fibers seen in the latest
biopsies from patients 3, 6, 7, and 8, reached a “point of
no return” and are unlikely to be rescued). Unfortu-
nately, there is no clear-cut definition of what exactly
“early” means. All CRIM-positive patients in this studywere ventilator-independent and began therapy within
7 months of age, which is traditionally considered to be an
“early” start. However, the outcome is suboptimal in many
cases. Our data suggest that we should re-think the treat-
ment paradigm for IPD and start considering “early” in
terms of days or weeks rather than months. Indeed, the
two patients in this study who responded best to therapy,
patients 1 and 4, began therapy earlier than others – at
five and two weeks, respectively; importantly, these two
individuals were free from most of the secondary symp-
toms seen in IPD patients on therapy. An early start of
therapy can be better achieved with the establishment of a
newborn screening program; our results and those
obtained in Taiwanese patients [33,34] strongly argue in
favor of such a program. A long-term follow-up of pa-
tients identified by newborn screening would be of the ut-
most importance.Conclusions
This is the first report on the impact of rhGAA ERT on
lysosomal glycogen accumulation and autophagic
buildup in some of the oldest survivors of classic IPD.
Despite long-term and regular administration of ERT,
clinical and histological evidence from this study show
that muscle damage persists and may increase in many
patients. The balance between glycogen transport to ly-
sosomes and its degradation by the drug tips in favor of
lysosomal accumulation of the substrate as patients with
IPD become older. Autophagic pathology emerges on
ERT, particularly in fibers with little lysosomal abnor-
mality. The best outcomes were observed in patients
who began therapy the earliest, emphasizing the appar-
ent benefits of newborn screening. The ethical aspects of
such screening remain open to consideration.Additional files
Additional file 1: Figure S1. Analysis of quadriceps muscle biopsy from
Patient 2 prior to and following 12 and 96 months of ERT. (A) Epon-
embedded PAS/Richardson’s-stained section shows mild to extensive
vacuolation in many fibers (magnification 25×). (B) At a higher
magnification (630×), it is evident that nearly all fibers are at least mildly
affected. There is evidence of fibrosis and myophagocytosis. (C, D) After
12 months of ERT (age 19.0 months, or 17.6 months CGA), fewer fibers
are effaced overall, and normal looking fibers can be seen (25× and
630×, respectively). (E) After 96 months of ERT (age 103.0 months, or
101.6 months CGA), some sections show regions with effaced or
prominently vacuolated fibers (top), whereas other sections show mildly
affected and normal looking fibers (bottom) (25×). Similar observations
are noted at a higher magnification (F, top and bottom; 100× and 630×,
respectively). The data are confirmed by H&E (G; 25×) and PASD (H, top
and bottom; 630×) staining. There is little interstitial fibrosis even in the
more affected areas (H, top; H, bottom: less affected area). (I) LAMP2/LC3
staining demonstrates prominent autophagic buildup (top fiber;
arrowheads) in many fibers, rare fibers with large expanded lysosomes
(middle; arrows), and fibers with autofluorescent inclusions (bottom,
open arrowheads). Bar: 10 μm.
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http://www.ojrd.com/content/8/1/90Additional file 2: Figure S2. Analysis of quadriceps muscle biopsy from
Patient 3 prior to and following 12 and 85 months of ERT. (A) Epon-
embedded toluidine blue/PAS-stained section shows mild to extensive
vacuolation (magnification 25×). (B) At a higher magnification (100×), it is
evident that nearly all fibers are at least mildly affected. There is minimal
fibrosis. (C, D) After 12 months of ERT (age 17.4 months, or 16.9 months
CGA), more fibers are effaced overall and there is severe fibrosis (C; 25×);
autophagic debris (C) is detected at a higher magnification (D; circled;
630×). (E) After 85 months of ERT (age 90.4 months, or 89.9 months CGA),
H&E-stained frozen sections show complete effacement of myofibrillar
architecture (50×). (F) LAMP2/LC3 immunostaining demonstrates near‐
complete destruction of muscle fibers. Bar: 10 μm.
Additional file 3: Figure S3. Analysis of quadriceps muscle biopsy from
Patient 4 after 77 months of ERT (age 77.5 months, or 77.2 months CGA).
(A) H&E-stained frozen section shows the presence of vacuolated fibers in
some fascicles (magnification 25×). Overall, muscle fibers are largely intact
with limited evidence of regeneration (i.e., internal nuclei). (B) PAS-D
staining demonstrates intact internal fiber architecture in most fibers, and
no significant increase in interstitial stroma (630×). (C) Epon-embedded
toluidine blue-stained section shows autophagic debris in mildly-affected
fibers (circled; 630×). (D) LAMP2/LC3 immunostaining demonstrates
largely intact muscle fibers (for example, top fiber in top panel)
interspersed with moderately affected muscle fibers with prominent
autophagic pathology (arrowheads). Bar: 10 μm.
Additional file 4: Figure S4. Analysis of muscle biopsies from Patient 5
after 83 and 84 months of ERT. (A) H&E-stained frozen section shows the
variation in pathology within a quadriceps biopsy: badly damaged
fascicles are seen adjacent to largely intact ones; there is some evidence
of regeneration (i.e., internal nuclei) (magnification 25×). (B, left and right)
PAS-D staining demonstrates relatively intact fibers next to completely
effaced ones; interstitial stroma are increased (630×). (C) Epon-embedded
toluidine blue-stained section (630×) shows vacuolization in many fibers.
(D, E) LAMP2/LC3 immunostaining demonstrates great variability of
muscle fiber involvement in biopsies from both quadriceps (D) and SCM
(E) muscles: a normal fiber (D; top fiber) next to a completely destroyed one
(D; bottom fiber), a fiber with autophagic buildup (the buildup is seen in
~10 % of fibers) (E; arrowheads), and fibers with largely expanded lysosomes
(E; arrows). Bar: 10 μm. (F; 25×) H&E-stained paraffin section of SCM muscle
shows variation in pathology: severely damaged fascicles adjacent to less
affected fascicles; there is some evidence of regeneration (i.e., internal nuclei);
note the focal reactive mononuclear inflammation (lower right). Note: The
images in A-D show tissue from the quadriceps biopsy taken after 84 months
of ERT (age 86.9 months). The images in E and F show tissue from the SCM
biopsy taken after 83 months of ERT (age 85.9 months).
Additional file 5: Figure S5. Analysis of quadriceps muscle biopsy from
Patient 6 after 49 months of ERT (age 56.0 months, or 55.0 months CGA).
(A) H&E-stained frozen section shows the pattern of damage and fibrosis:
vacuolization of more than 50% of myocytes, interspersed with fibers
showing intact myofibrillar architecture and some internal nuclei
indicating regeneration (magnification 25×). (B) PAS-D staining
demonstrates relatively intact fibers in close proximity to completely
effaced ones and increased interstitial stroma (630×). (C) Epon-embedded
toluidine blue-stained section confirms the results obtained with H&E
and PAS-D staining (630×). (D) LAMP2/LC3 immunostaining further
demonstrates variability of muscle fiber involvement: a completely
destroyed fiber (top fiber), a relatively preserved fiber with moderately
enlarged lysosomes (middle fiber), and a fiber with autophagic
accumulation (bottom fiber, arrowheads). Bar: 10 μm.
Additional file 6: Figure S6. Analysis of soleus muscle biopsy from Patient
8 after 18 months of ERT (age 24.0 months). (A) H&E-stained frozen section
shows the extent of damage and fibrosis: severe, diffuse vacuolization of more
than 95% of myocytes (magnification 25×). (B) PAS-D staining demonstrates
loss of internal muscle architecture in virtually all fibers (only lace-like remnants
can be seen); there is an increase in interstitial stroma (630×). (C) Epon-
embedded toluidine blue-stained section highlights the obliteration of
sarcoplasm by small vesicular structures (630×). (D) LAMP2/LC3
immunostaining demonstrates complete destruction of myofibers with a few
identifiable autophagosomes (arrows) in the top fiber. Bar: 10 μm.Abbreviations
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